†rsrapport Nycomed - Takeda Pharmaceuticals International GmbH

ACCOUNTSPARENT COMPANY ACCOUNTS NOTES7. Shareholder’s equity2000 1998/99(000)DKK(000)DKK7 monthsShare capitalShare capital beginning of the year 10,000 500Capital increase 10 9,50010,010 10,000Share premiumShare premium beginning of the year 745,680 0Share premium from capital increase in the year 31,092 804,044Transferred from retained earnings - 101,345 - 58,364675,427 745,680Retained earningsRetained earnings beginning of the year 0 0Adjustment of goodwill -30,279 0Foreign currency conversion effect foreign subsidiaries - 27,856 - 1,295Transferred from profit distribution - 43,210 -57,069Transferred to share premium 101,345 58,3640 0Total shareholder’s equity 685,437 755,680The share capital comprises 1,001,001 sharesof DKK 108. Long term debtFinancial institutions 0 177,394Other long term debt 562,982 500,226Total debt 562,982 677,620Repayment in 2001 0 150,103Long term debt 562,982 527,517Total long term debt due more than 5 years after thebalance sheet date 562,982 500,2269. Payables to affiliated entitiesNycomed Amersham plc, England 71,973 0Nycomed Pharma Holding AS, Norway 1,669 0Nycomed Danmark A/S 281 0Total 73,923 0–59–